{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T15:24:28Z","timestamp":1743693868378,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100018551","name":"Science and Technology Innovation Talents in Universities of Henan Province","doi-asserted-by":"publisher","award":["LHGJ20190062"],"award-info":[{"award-number":["LHGJ20190062"]}],"id":[{"id":"10.13039\/501100018551","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s10067-024-06982-9","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T15:01:32Z","timestamp":1714662092000},"page":"1845-1853","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Changes in metabolic parameters and serum YKL-40 levels in Chinese rheumatoid arthritis patients during tocilizumab therapy"],"prefix":"10.1007","volume":"43","author":[{"given":"Wenlu","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanxia","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelei","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panpan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingbo","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaofeng","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qihua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3039-8676","authenticated-orcid":false,"given":"Tianfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"6982_CR1","doi-asserted-by":"publisher","first-page":"2453265","DOI":"10.1155\/2018\/2453265","volume":"2018","author":"F Cacciapaglia","year":"2018","unstructured":"Cacciapaglia F, Anelli M, Rinaldi A et al (2018) Lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment. Mediat Inflamm 2018:2453265. https:\/\/doi.org\/10.1155\/2018\/2453265","journal-title":"Mediat Inflamm"},{"key":"6982_CR2","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.3390\/ijms20184633","volume":"20","author":"E Hoffman","year":"2019","unstructured":"Hoffman E, Rahat MA, Feld J et al (2019) Effects of tocilizumab, an anti-interleukin-6 receptor antibody, on serum lipid and adipokine levels in patients with rheumatoid arthritis. Int J Mol Sci 20:4633. https:\/\/doi.org\/10.3390\/ijms20184633","journal-title":"Int J Mol Sci"},{"key":"6982_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrrheum.2013.91","volume":"9","author":"J Robertson","year":"2013","unstructured":"Robertson J, Peters M, McInnes I, Sattar N (2013) Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 9:513\u2013523. https:\/\/doi.org\/10.1038\/nrrheum.2013.91","journal-title":"Nat Rev Rheumatol"},{"key":"6982_CR4","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1002\/art.22033","volume":"54","author":"RN Maini","year":"2006","unstructured":"Maini RN, Taylor PC, Szechinski J et al (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817\u20132829. https:\/\/doi.org\/10.1002\/art.22033","journal-title":"Arthritis Rheum"},{"key":"6982_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13075-015-0559-8","volume":"17","author":"D Chen","year":"2015","unstructured":"Chen D, Chen Y, Hsieh T, Hsieh C, Lin C, Lan J (2015) Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Res Ther 17:52. https:\/\/doi.org\/10.1186\/s13075-015-0559-8","journal-title":"Arthritis Res Ther"},{"key":"6982_CR6","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1136\/annrheumdis-2017-211708","volume":"76","author":"J Robertson","year":"2017","unstructured":"Robertson J, Porter D, Sattar N et al (2017) Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. Ann Rheum Dis 76:1949\u20131952. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211708","journal-title":"Ann Rheum Dis"},{"key":"6982_CR7","doi-asserted-by":"publisher","first-page":"e14006","DOI":"10.1111\/eci.14006","volume":"53","author":"I Ferraz-Amaro","year":"2023","unstructured":"Ferraz-Amaro I, Santos-Concepci\u00f3n S, Castro J et al (2023) Tocilizumab-related hypertriglyceridemia is independent of key molecules regulating lipid metabolism. Eur J Clin Invest 53:e14006. https:\/\/doi.org\/10.1111\/eci.14006","journal-title":"Eur J Clin Invest"},{"key":"6982_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.autrev.2017.11.030","volume":"17","author":"F Ursini","year":"2018","unstructured":"Ursini F, Russo E, Ruscitti P, Giacomelli R, De Sarro G (2018) The effect of non-TNF-targeted biologics and small molecules on insulin resistance in inflammatory arthritis. Autoimmun Rev 17:399\u2013404. https:\/\/doi.org\/10.1016\/j.autrev.2017.11.030","journal-title":"Autoimmun Rev"},{"key":"6982_CR9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/jcsm.12189","volume":"8","author":"A Tournadre","year":"2017","unstructured":"Tournadre A, Pereira B, Dutheil F et al (2017) Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J Cachexia Sarcopenia Muscle 8:639\u2013646. https:\/\/doi.org\/10.1002\/jcsm.12189","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"6982_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10067-014-2704-1","volume":"34","author":"K Makrilakis","year":"2015","unstructured":"Makrilakis K, Fragiadaki K, Smith J, Sfikakis P, Kitas G (2015) Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade. Clin Rheumatol 34:419\u2013427. https:\/\/doi.org\/10.1007\/s10067-014-2704-1","journal-title":"Clin Rheumatol"},{"key":"6982_CR11","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1136\/ard.2010.132845","volume":"70","author":"A Ogata","year":"2011","unstructured":"Ogata A, Morishima A, Hirano T et al (2011) Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab. Ann Rheum Dis 70:1164\u20131165. https:\/\/doi.org\/10.1136\/ard.2010.132845","journal-title":"Ann Rheum Dis"},{"key":"6982_CR12","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.7150\/ijbs.67587","volume":"18","author":"K Tizaoui","year":"2022","unstructured":"Tizaoui K, Yang J, Lee K et al (2022) The role of YKL-40 in the pathogenesis of autoimmune diseases: a comprehensive review. Int J Biol Sci 18:3731\u20133746. https:\/\/doi.org\/10.7150\/ijbs.67587","journal-title":"Int J Biol Sci"},{"key":"6982_CR13","doi-asserted-by":"publisher","first-page":"19172","DOI":"10.1038\/s41598-023-46491-4","volume":"13","author":"M V\u00e1zquez-Del Mercado","year":"2023","unstructured":"V\u00e1zquez-Del Mercado M, P\u00e9rez-V\u00e1zquez F, M\u00e1rquez-Aguirre AL et al (2023) YKL-40 serum levels are predicted by inflammatory state, age and diagnosis of idiopathic inflammatory myopathies. Sci Rep 13:19172. https:\/\/doi.org\/10.1038\/s41598-023-46491-4","journal-title":"Sci Rep"},{"key":"6982_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/clinchem\/44.3.509","volume":"44","author":"S Harvey","year":"1998","unstructured":"Harvey S, Weisman M, O\u2019Dell J et al (1998) Chondrex: new marker of joint disease. Clin Chem 44:509\u2013516","journal-title":"Clin Chem"},{"key":"6982_CR15","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1136\/ard.59.7.544","volume":"59","author":"K Vos","year":"2000","unstructured":"Vos K, Steenbakkers P, Miltenburg AM et al (2000) Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 59:544\u2013548. https:\/\/doi.org\/10.1136\/ard.59.7.544","journal-title":"Ann Rheum Dis"},{"key":"6982_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1515\/folmed-2017-0013","volume":"59","author":"MH Kazakova","year":"2017","unstructured":"Kazakova MH, Batalov AZ, Mateva NG, Kolarov ZG, Sarafian VS (2017) YKL-40 and cytokines - a New Diagnostic Constellation in Rheumatoid Arthritis? Folia Med 59:37\u201342. https:\/\/doi.org\/10.1515\/folmed-2017-0013","journal-title":"Folia Med"},{"key":"6982_CR17","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/rheumatology\/38.7.618","volume":"38","author":"J Johansen","year":"1999","unstructured":"Johansen J, Stoltenberg M, Hansen M et al (1999) Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology 38:618\u2013626. https:\/\/doi.org\/10.1093\/rheumatology\/38.7.618","journal-title":"Rheumatology"},{"key":"6982_CR18","doi-asserted-by":"publisher","first-page":"1211790","DOI":"10.3389\/fimmu.2023.1211790","volume":"14","author":"R Yu","year":"2023","unstructured":"Yu R, Liu X, Deng X et al (2023) Serum CHI3L1 as a biomarker of interstitial lung disease in rheumatoid arthritis. Front Immunol 14:1211790. https:\/\/doi.org\/10.3389\/fimmu.2023.1211790","journal-title":"Front Immunol"},{"key":"6982_CR19","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-020-00303-7","volume":"5","author":"T Zhao","year":"2020","unstructured":"Zhao T, Su Z, Li Y, Zhang X, You Q (2020) Chitinase-3 like-protein-1 function and its role in diseases. Signal Transduct Targeted Ther 5:201. https:\/\/doi.org\/10.1038\/s41392-020-00303-7","journal-title":"Signal Transduct Targeted Ther"},{"key":"6982_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00011-006-0076-y","volume":"55","author":"CN Rathcke","year":"2006","unstructured":"Rathcke CN, Vestergaard H (2006) YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res 55:221\u2013227. https:\/\/doi.org\/10.1007\/s00011-006-0076-y","journal-title":"Inflamm Res"},{"key":"6982_CR21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1161\/strokeaha.114.007657","volume":"46","author":"AD Kjaergaard","year":"2015","unstructured":"Kjaergaard AD, Johansen JS, Bojesen SE, Nordestgaard BG (2015) Elevated plasma YKL-40, lipids and lipoproteins, and ischemic vascular disease in the general population. Stroke 46:329\u2013335. https:\/\/doi.org\/10.1161\/strokeaha.114.007657","journal-title":"Stroke"},{"key":"6982_CR22","doi-asserted-by":"publisher","first-page":"8713908","DOI":"10.1155\/2020\/8713908","volume":"2020","author":"Y Kwon","year":"2020","unstructured":"Kwon Y, Kim J, Ha E et al (2020) Serum YKL-40 levels are associated with the atherogenic index of plasma in children. Mediat Inflamm 2020:8713908. https:\/\/doi.org\/10.1155\/2020\/8713908","journal-title":"Mediat Inflamm"},{"key":"6982_CR23","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.metabol.2011.09.004","volume":"61","author":"I Kyrgios","year":"2012","unstructured":"Kyrgios I, Galli-Tsinopoulou A, Stylianou C, Papakonstantinou E, Arvanitidou M, Haidich A (2012) Elevated circulating levels of the serum acute-phase protein YKL-40 (chitinase 3-like protein 1) are a marker of obesity and insulin resistance in prepubertal children. Metabolism 61:562\u2013568. https:\/\/doi.org\/10.1016\/j.metabol.2011.09.004","journal-title":"Metabolism"},{"key":"6982_CR24","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/jocd.13124","volume":"19","author":"A Ebrahim","year":"2020","unstructured":"Ebrahim A, Mustafa A, El-Shimi O, Fathy M (2020) Serum YKL40: A novel potential link between inflammation and dyslipidemia in acne vulgaris. J Cosmet Dermatol 19:1219\u20131223. https:\/\/doi.org\/10.1111\/jocd.13124","journal-title":"J Cosmet Dermatol"},{"key":"6982_CR25","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nrrheum.2014.121","volume":"10","author":"G Kerekes","year":"2014","unstructured":"Kerekes G, Nurmohamed MT, Gonz\u00e1lez-Gay MA et al (2014) Rheumatoid arthritis and metabolic syndrome. Nat Rev Rheumatol 10:691\u2013696. https:\/\/doi.org\/10.1038\/nrrheum.2014.121","journal-title":"Nat Rev Rheumatol"},{"key":"6982_CR26","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s13075-020-02297-7","volume":"22","author":"E Toussirot","year":"2020","unstructured":"Toussirot E, Marotte H, Mulleman D et al (2020) Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study. Arthritis Res Ther 22:224. https:\/\/doi.org\/10.1186\/s13075-020-02297-7","journal-title":"Arthritis Res Ther"},{"key":"6982_CR27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.cyto.2012.11.007","volume":"61","author":"S Younis","year":"2013","unstructured":"Younis S, Rosner I, Rimar D et al (2013) Weight change during pharmacological blockade of interleukin-6 or tumor necrosis factor-\u03b1 in patients with inflammatory rheumatic disorders: a 16-week comparative study. Cytokine 61:353\u2013355. https:\/\/doi.org\/10.1016\/j.cyto.2012.11.007","journal-title":"Cytokine"},{"key":"6982_CR28","first-page":"293","volume":"37","author":"A Fioravanti","year":"2019","unstructured":"Fioravanti A, Tenti S, Bacarelli MR et al (2019) Tocilizumab modulates serum levels of adiponectin and chemerin in patients with rheumatoid arthritis: potential cardiovascular protective role of IL-6 inhibition. Clin Exp Rheumatol 37:293\u2013300 (undefined)","journal-title":"Clin Exp Rheumatol"},{"key":"6982_CR29","doi-asserted-by":"publisher","first-page":"e14328","DOI":"10.1371\/journal.pone.0014328","volume":"5","author":"O Schultz","year":"2010","unstructured":"Schultz O, Oberhauser F, Saech J et al (2010) Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS ONE 5:e14328. https:\/\/doi.org\/10.1371\/journal.pone.0014328","journal-title":"PLoS ONE"},{"key":"6982_CR30","first-page":"655","volume":"19","author":"T Matsumoto","year":"2001","unstructured":"Matsumoto T, Tsurumoto T (2001) Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laborarory parameters. Clin Exp Rheumatol 19:655\u2013660","journal-title":"Clin Exp Rheumatol"},{"key":"6982_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/03009742.2017.1376107","volume":"47","author":"CH Brahe","year":"2018","unstructured":"Brahe CH, Dehlendorff C, \u00d8stergaard M et al (2018) Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials. Scand J Rheumatol 47:259\u2013269. https:\/\/doi.org\/10.1080\/03009742.2017.1376107","journal-title":"Scand J Rheumatol"},{"key":"6982_CR32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00011-005-0010-8","volume":"55","author":"CN Rathcke","year":"2006","unstructured":"Rathcke CN, Johansen JS, Vestergaard H (2006) YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res 55:53\u201359. https:\/\/doi.org\/10.1007\/s00011-005-0010-8","journal-title":"Inflamm Res"},{"key":"6982_CR33","doi-asserted-by":"publisher","first-page":"e47094","DOI":"10.1371\/journal.pone.0047094","volume":"7","author":"S Thomsen","year":"2012","unstructured":"Thomsen S, Rathcke C, Skaaby T, Linneberg A, Vestergaard H (2012) The Association between genetic variations of CHI3L1, levels of the encoded glycoprotein YKL-40 and the lipid profile in a Danish population. PLoS ONE 7:e47094. https:\/\/doi.org\/10.1371\/journal.pone.0047094","journal-title":"PLoS ONE"},{"key":"6982_CR34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1475-2840-11-84","volume":"11","author":"HM Kim","year":"2012","unstructured":"Kim HM, Lee BW, Song YM et al (2012) Potential association between coronary artery disease and the inflammatory biomarker YKL-40 in asymptomatic patients with type 2 diabetes mellitus. Cardiovasc Diabetol 11:84. https:\/\/doi.org\/10.1186\/1475-2840-11-84","journal-title":"Cardiovasc Diabetol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06982-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-06982-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06982-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T16:06:14Z","timestamp":1716393974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-06982-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["6982"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-06982-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2024,5,2]]},"assertion":[{"value":"26 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethical Committee of the First Affiliated Hospital of Zhengzhou University (approval number: 2021-KY-0053). Written informed consent forms were obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All the authors have declared no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}